01—Abstract
Summary
Summary of the 10-Q filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported strong financial results for the second quarter and first half of 2024, demonstrating robust revenue growth and increased profitability.
Total revenues increased by 12% year-over-year for the second quarter to $3.55 billiona and by 6% for the first half to $6.69 billion, driven by significant contributions from its key products, particularly Dupixent and EYLEA HD. Net product sales saw a healthy increase, with Dupixent sales up 27% in the second quarter and 26% in the first half. EYLEA HD and EYLEA combined U.S. net sales showed a slight increase of 2%, with EYLEA HD sales contributing $304.2 million in the quarter, reflecting strong patient adoption.
Collaboration revenue also saw a substantial increase, primarily due to higher profit shares from Dupixent sales. The company's net income grew significantly, reaching $1.43 billionb in the second quarter, a 48% increase year-over-year, resulting in diluted EPS of $12.41.
For the first half, net income increased by 21% to $2.15 billionc, with diluted EPS of $18.68. The company also continued its share repurchase program, repurchasing $601.4 million in the second quarter, underscoring a commitment to returning capital to shareholders.
02—Key points
Key Highlights
- Total revenues increased by 12% to $3.55 billion in Q2 2024 and by 6% to $6.69 billion in H1 2024, driven by strong product sales and collaboration revenues.
- Net product sales for Dupixent increased by 27% in Q2 and 26% in H1, showcasing continued strong market performance.
- EYLEA HD and EYLEA combined U.S. net sales grew by 2% in H1 2024, with EYLEA HD contributing $304.2 million in Q2 as patient adoption continues.
- Net income surged by 48% to $1.43 billion in Q2 2024, resulting in diluted EPS of $12.41, up from $8.50 in the prior year period.
- Research and development expenses increased by 11% year-over-year for the quarter, indicating continued investment in pipeline advancement.
- The company actively managed its capital, repurchasing $601.4 million of common stock in Q2 2024, and had $3.631 billion remaining under its share repurchase programs as of June 30, 2024.
- The company's cash and cash equivalents decreased from $2.73 billion to $1.92 billion, while marketable securities increased significantly, indicating strategic deployment of capital.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 1, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $3.55B$3.16B | +12.3% |
| R&D Expenses | $1.20B$1.09B | +10.6% |
| SG&A Expenses | $758.80M$652.00M | +16.4% |
| Operating Expenses | $2.48B$2.14B | +15.7% |
| Operating Income | $1.07B$1.02B | +5.2% |
| Net Income | $1.43B$968.40M | +47.9% |
| EPS (Basic) | $13.25$9.05 | +46.4% |
| EPS (Diluted) | $12.41$8.50 | +46.0% |
| Shares Outstanding (Basic) | 108.10M107.00M | +1.0% |
| Shares Outstanding (Diluted) | 115.40M113.90M | +1.3% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Regeneron's revenue growth in Q2 2024?
Regeneron's revenue growth in Q2 2024 was primarily driven by strong performance in net product sales, particularly from Dupixent, which saw a 27% increase year-over-year. Collaboration revenue also contributed significantly, boosted by higher profit shares from Dupixent sales. EYLEA HD and EYLEA combined U.S. net sales showed a modest 2% increase, with EYLEA HD sales demonstrating positive patient adoption.
How did Regeneron's profitability change in the second quarter of 2024 compared to the same period last year?
Regeneron's profitability saw a substantial improvement. Net income increased by 48% to $1.43 billion in Q2 2024, compared to $968.4 million in Q2 2023. This translated to a significant rise in diluted earnings per share (EPS) from $8.50 to $12.41.
What is the company's outlook regarding its share repurchase program?
Regeneron continued its share repurchase activities, repurchasing $601.4 million of its common stock in the second quarter of 2024. As of June 30, 2024, the company had approximately $3.631 billion remaining available under its authorized share repurchase programs, indicating a continued commitment to returning capital to shareholders.
What is the current status of Regeneron's key product EYLEA HD?
EYLEA HD, approved by the FDA in August 2023, is gaining traction in the market. In Q2 2024, EYLEA HD sales contributed $304.2 million in the U.S., reflecting successful patient adoption. Combined U.S. net sales for EYLEA HD and EYLEA grew by 2% in the first half of 2024.
06—Continue